GSK plc announced an investment of £1 billion over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries. This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR), which continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries. Specifically, the investment of £1 billion for Global Health R&D will support GSK's efforts to: Deliver next-generation vaccines and medicines for malaria and tuberculosis, offering shorter, simpler, safer treatment options for patients, including R&D on long-acting injectables to protect against P. falciparum malaria.

Through ViiV Healthcare, work in partnership towards the goal of ending HIV/AIDS by developing and enabling access to innovative treatment and prevention options for people affected by HIV. Reduce antibiotic resistance by advancing pipeline for vaccines, including first-in-class vaccines against invasive non-typhoidal salmonellosis and shigellosis. Catalyse external funding for R&D for high-burden infectious diseases through multi-sectoral collaborations and alliances.

To deliver against these targets, GSK has formed a dedicated, non-commercial Global Health Unit for which success is measured by health impact alone. The model is designed to prioritise the prevention and treatment of infectious diseases in lower-income countries where the Company's science can impact the health of millions in disease areas with little prospect of a commercial return on investment.